Neuroblastoma is a complicated pediatric tumor, originating from the neural crest, which is the most prevalent in adrenal glands, but may rarely be seen in some other tissues as well. Studies are focused on developing new strategies through novel chemo‐ and immuno‐therapeutic drug targets. Different types of oncogenes such as MYCN, tumor suppressor genes such as p53, and some structural genes such as vascular endothelial growth factor are considered as targets for neuroblastoma therapy. The individual expression patterns in NB cells make them appropriate for this purpose. The combined effect of nano‐drug delivery systems and specific drug targets will result in lower systemic side effects, prolonged therapeutic effects, and improvements in the pharmacokinetic properties of the drugs. Some of these novel drug delivery systems with a focus on liposomes as carriers are also discussed. In this review, genes and protein products that are beneficial as drug targets in the treatment of neuroblastoma have been discussed.

中文翻译：

---

神经母细胞瘤靶向纳米粒子和基于纳米技术的新型治疗方法。

神经母细胞瘤是一种复杂的儿科肿瘤，起源于神经嵴，在肾上腺中最常见，但在其他一些组织中也可能很少见到。研究的重点是通过新的化学和免疫治疗药物靶点开发新策略。MYCN等不同类型的癌基因、p53等抑癌基因和血管内皮生长因子等一些结构基因被认为是神经母细胞瘤治疗的靶点。NB 细胞中的个体表达模式使其适用于这一目的。纳米药物递送系统和特定药物靶点的联合作用将导致较低的全身副作用、延长治疗效果并改善药物的药代动力学特性。还讨论了一些以脂质体为载体的新型药物递送系统。在这篇综述中，讨论了作为治疗神经母细胞瘤的药物靶点有益的基因和蛋白质产品。